Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProteoMediX Raises CHF 3.2M (€2.6M) in Financing

Published: Wednesday, April 09, 2014
Last Updated: Wednesday, April 09, 2014
Bookmark and Share
The Company has announced the successful closing of a Series B equity financing round from existing and new investors.

The round was led by Altos Venture (Allschwil, Switzerland), a Swiss venture capital firm chaired by Dr. Walter Fischli (co-founder of Actelion), that is investing in carefully selected hightech start-ups. All existing investors also participated in this round, including Zürcher Kantonalbank and several private investors experienced in life science investments.

The new funds will enable ProteoMediX to continue the development of its lead product for the early diagnosis of prostate cancer. The test is intended as an aid in the detection of prostate cancer, i.e. to inform men with elevated PSA (prostate specific antigen) and or suspicious DRE (digital rectal examination), about the likelihood of having a positive biopsy. The goal is to significantly reduce unnecessary prostate biopsies (today, 3 out of 4 biopsies are negative).

ProteoMediX achieved significant milestones in the past two years. The test format was changed from mass spectrometry to immunoassay in order to be compatible with today’s standard technology platform in diagnostic laboratories. In a recent pilot study, the successful platform change was confirmed and the promising results showed that ProteoMediX’ test has the potential to reduce significantly more than 50% of negative prostate biopsies.

Dr. Ralph Schiess, CEO and co-founder commented: “We are delighted to have received this strong support from investors. The funds will enable us to further advance our test for the reduction of unnecessary biopsies by gathering additional data from clinical studies”. “We are pleased that we attracted new investors and that all existing investors participated in this financing round. This is a strong validation of our company and recognizes the progress we made.”, said Christian Brühlmann, CFO and co-founder of ProteoMediX.
 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
New Tech Enables Epigenomic Analysis with a Mere 100 Cells
A new technology that will dramatically enhance investigations of epigenomes, the machinery that turns on and off genes and a very prominent field of study in diseases such as stem cell differentiation, inflammation and cancer has been developed by researchers at Virginia Tech.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Study Finds Non-Genetic Cancer Mechanism
Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!